|Articles|June 27, 2011
Linagliptin cardiovascular safety profile appears superior to glimepiride
Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.
Advertisement
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Medical Economics
1
Remote monitoring boosts Medicare revenue by 20% for primary care practices, study finds
2
10 U.S. cities with the worst inflation in 2025
3
Preview: Can independent medical practices still succeed? Our expert panel
4
As health systems grow, low-income Medicare patients lose ground, RAND study finds
5















